Hoth Therapeutics (NASDAQ:HOTH) Announces Earnings Results, Beats Expectations By $0.07 EPS

Hoth Therapeutics (NASDAQ:HOTH) released its earnings results on Friday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07, Zacks reports.

Hoth Therapeutics Stock Up 3.0 %

Shares of HOTH stock traded up $0.03 on Friday, reaching $1.03. 132,124 shares of the stock were exchanged, compared to its average volume of 3,413,480. The stock has a market cap of $7.11 million, a P/E ratio of -0.78 and a beta of 0.84. The firm has a 50 day moving average of $1.14 and a two-hundred day moving average of $1.01. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80.

Wall Street Analysts Forecast Growth

HOTH has been the topic of several analyst reports. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a report on Monday, March 10th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.